TPST
NASDAQTempest Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.03-0.81 (-43.75%)
2026-05-192026-08-21
News · 26 weeks59-11%
2026-03-012026-08-23
Mix3190d
- SEC Filings21(68%)
- Insider5(16%)
- Other3(10%)
- Leadership2(6%)
Latest news
25 items- SECSEC Form 8-K filed by Tempest Therapeutics Inc.8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-1 filed by Tempest Therapeutics Inc.S-1 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form DEFA14A filed by Tempest Therapeutics Inc.DEFA14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form 10-Q filed by Tempest Therapeutics Inc.10-Q - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Reports Second Quarter 2026 Financial Results and Provides Business UpdateExecuted a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027 Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology compan
- SECSEC Form DEFA14A filed by Tempest Therapeutics Inc.DEFA14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Entry into a Material Definitive Agreement8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-TTempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indicationsSenlang Biotechnology, a clinical-stage cell therapy company with established expertise in CD7-targeted CAR-T development, will conduct a first-in-human investigator-initiated trial of TPST-4003 in approximately 10 patients with neurological autoimmune diseases, initially including myasthenia gravis and multiple sclerosis, with first patient dosing expected in the fourth quarter of 2026 BRISBANE, Calif., July 21, 2026 (GLOBE N
- SECSEC Form DEF 14A filed by Tempest Therapeutics Inc.DEF 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approachLead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indicationsFirst investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG and MS, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027 BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Th
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form PRE 14A filed by Tempest Therapeutics Inc.PRE 14A - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-3 filed by Tempest Therapeutics Inc.S-3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- INSIDERCEO and President Angel Matthew bought $500,001 worth of shares (231,482 units at $2.16) (SEC Form 4)4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- SECSEC Form 8-K filed by Tempest Therapeutics Inc.8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form D filed by Tempest Therapeutics Inc.D - Tempest Therapeutics, Inc. (0001544227) (Filer)
- INSIDERSEC Form 4 filed by Director Yee John D.4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yee John D.3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERNew insider Richey William Drake claimed ownership of 2,000 shares (SEC Form 3)3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERSEC Form 4 filed by Director Richey William Drake4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
TPST FAQ
6 questionsWhat does Tempest Therapeutics Inc. do?
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.Where does TPST stock trade?
Tempest Therapeutics Inc. (TPST) is listed on NASDAQ.What sector and industry is TPST in?
Tempest Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TPST?
Tempest Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1100.00 price target on 2026-01-22. Recent price targets range from $1100.00 to $1500.00.What companies are similar to TPST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TPST side-by-side with any of them on Quantisnow.How can I track TPST on Quantisnow?
Quantisnow aggregates Tempest Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TPST to receive live email and push alerts on every new disclosure.